About The Study: Ivonescimab plus chemotherapy significantly improved progression-free survival with tolerable safety profile in patients with non–small cell lung cancer who previously underwent EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment and may offer a new treatment option for patients with TKI resistance.
Quote from corresponding author Li Zhang, M.D.:
"For patients with non-small cell lung cancer whose illness has progressed while receiving EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy, especially the third generation TKIs, optimal treatment options remain limited.
"This randomized, placebo-controlled phase 3 study demonstrated ivonescimab plus chemotherapy significantly improved progression-free survival (7.1 vs 4.8 months) compared with chemotherapy alone in TKI-treated non-small cell lung cancer.
"Based on the results of this study, ivonescimab has been approved in China as a new treatment option for those patients. An international multi-center study of this treatment regimen is ongoing."
